Literature DB >> 8759879

Multiple myeloma: almost all patients are cytogenetically abnormal.

M Zandecki1, J L Laï, T Facon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8759879     DOI： 10.1046/j.1365-2141.1996.d01-2939.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  17 in total

1.  Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

Authors:  Shrikanta Chattopadhyay; Alison L Stewart; Siddhartha Mukherjee; Cherrie Huang; Kimberly A Hartwell; Peter G Miller; Radhika Subramanian; Leigh C Carmody; Rushdia Z Yusuf; David B Sykes; Joshiawa Paulk; Amedeo Vetere; Sonia Vallet; Loredana Santo; Diana D Cirstea; Teru Hideshima; Vlado Dančík; Max M Majireck; Mahmud M Hussain; Shambhavi Singh; Ryan Quiroz; Jonathan Iaconelli; Rakesh Karmacharya; Nicola J Tolliday; Paul A Clemons; Malcolm A S Moore; Andrew M Stern; Alykhan F Shamji; Benjamin L Ebert; Todd R Golub; Noopur S Raje; David T Scadden; Stuart L Schreiber
Journal:  Cell Rep       Date:  2015-02-05       Impact factor: 9.423

2.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

3.  A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Authors:  Zhong Chen; Bonnie Issa; Shiang Huang; Emily Aston; Jia Xu; Margaret Yu; Arthur R Brothman; Martha Glenn
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

4.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.

Authors:  Y-F Song; R Xu; X-H Zhang; B-B Chen; Q Chen; Y-M Chen; Y Xie
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

6.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

Review 7.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

Review 8.  Molecular biology of myeloma.

Authors:  N C Gutiérrez; R García-Sanz; J F San Miguel
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

9.  Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Authors:  Jun Inoue; Takemi Otsuki; Akira Hirasawa; Issei Imoto; Yoshinobu Matsuo; Shiroh Shimizu; Masafumi Taniwaki; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Authors:  Reinaldo Franqui-Machin; Mu Hao; Hua Bai; Zhimin Gu; Xin Zhan; Hasem Habelhah; Yogesh Jethava; Lugui Qiu; Ivana Frech; Guido Tricot; Fenghuang Zhan
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.